The type 2 diabetes market is forecasted to grow by USD 53.8 billion during 2024-2029, accelerating at a CAGR of 12.2% during the forecast period. The report on the type 2 diabetes market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of diabetes, rise in prevalence of obesity and changing lifestyles, and recent product approvals.
Market Scope |
Base Year | 2025 |
End Year | 2029 |
Series Year | 2025-2029 |
Growth Momentum | Accelerate |
YOY 2025 | 10.5% |
CAGR | 12.2% |
Incremental Value | $53.8 bn |
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
Technavio's type 2 diabetes market is segmented as below:
By Drug Class
- Insulin
- DPP-4 inhibitor
- GLP-1 receptor agonists
- SGLT-2 inhibitors
- Others
By Distribution Channel
- Retail pharmacies
- Hospital pharmacies
- Online pharmacies
By Delivery Mode
- Oral
- Injectable
- Continuous glucose monitoring (CGM)
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the growing geriatric population as one of the prime reasons driving the type 2 diabetes market growth during the next few years. Also, increase in awareness of diabetes and growing initiatives and innovations in therapies will lead to sizable demand in the market.
The report on the type 2 diabetes market covers the following areas:
- Type 2 Diabetes Market sizing
- Type 2 Diabetes Market forecast
- Type 2 Diabetes Market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading type 2 diabetes market vendors that include Amgen Inc., AstraZeneca PLC, Baxter International Inc., Biocon Ltd., Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Ltd., Daiichi Sankyo Co. Ltd., DM Pharma Marketing Pvt. Ltd., Eli Lilly and Co., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Johnson and Johnson Services Inc., Merck KGaA, Novartis AG, Novo Nordisk AS, Pfizer Inc., Practo Technologies Pvt. Ltd., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and Tonghua Dongbao Pharmaceutical Co. Ltd.. Also, the type 2 diabetes market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.